Clinical Trials Logo

Lung Diseases, Interstitial clinical trials

View clinical trials related to Lung Diseases, Interstitial.

Filter by:

NCT ID: NCT03901534 Recruiting - Clinical trials for Obstructive Sleep Apnea

Assessment of Continuous Positive Airway Pressure Therapy in IPF

ACT-IPF
Start date: January 1, 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate whether biomarkers of lung injury and remodeling are responsive to effective continuous positive airway pressure (CPAP) treatment in adults with idiopathic pulmonary fibrosis (IPF) and moderate-to-severe obstructive sleep apnea (OSA).

NCT ID: NCT03901196 Recruiting - Clinical trials for Idiopathic Pulmonary Fibrosis

Multi-elemental Imaging of Lung Tissues With LIBS (Laser-induced Breakdown Spectroscopy)

MEDICO-LIBS
Start date: January 22, 2020
Phase:
Study type: Observational

Evaluate the feasibility of performing a multi-elemental imaging analysis of lung specimens from patients with ILDs, with an technology named LIBS (Laser Induced-Breakdown Spectroscopy)

NCT ID: NCT03857854 Recruiting - Clinical trials for Dermatomyositis Interstitial Lung Disease (Dm-ILD)

Efficacy and Safety of Pirfenidone in Patient With Dermatomyositis Interstitial Lung Disease (Dm-ILD)

Start date: June 5, 2018
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of pirfenidone in subjects with dermatomyositis interstitial lung disease

NCT ID: NCT03856853 Recruiting - Clinical trials for Systemic Sclerosis-associated Interstitial Lung Disease (Ssc-ild)

Efficacy and Safety of Pirfenidone in Patient With Systemic Sclerosis-associated Interstitial Lung Disease

Start date: June 15, 2018
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the eEfficacy and safety of pirfenidone in subjects with systemic sclerosis-associated interstitial lung disease (SSc-ILD)

NCT ID: NCT03836417 Recruiting - Clinical trials for Idiopathic Pulmonary Fibrosis

Molecular Diagnosis of Idiopathic Interstitial Pneumonias: a Prospective Study

Start date: June 28, 2019
Phase:
Study type: Observational

Molecular diagnosis of idiopathic interstitial pneumonias is an innovative way to potentially improve the diagnostic accuracy of surgical lung biopsies (SLBs), introducing molecular classifiers of idiopathic pulmonary fibrosis (IPF) vs. non-specific interstitial pneumonia (NSIP) vs. chronic hypersensitivity pneumonitis (CHP). The investigators hypothesize that pre-defined gene expression profiles previously identified on large lung explants can still be identified and reproducible on smaller, clinically available surgical lung biopsies (SLBs), and can be used to increase diagnostic accuracy during multi-disciplinary discussion. The investigators also hypothesize that the expression level of individual, preselected genes that accurately differentiate IPF from NSIP and CHP on lung explants can be reproduced on SLBs. The investigators will isolate RNA from SLBs obtained from patients with IIP and perform microarray analysis to verify the reproducibility of gene expression profiles on SLBs. Individual genes expression levels will be determined by RT-PCR. The diagnosis will be determined by MDD and further validated by prospective follow-up of patients for a period of 3 years. The investigators will assess the impact of molecular diagnostic techniques on interobserver agreement during multi-disciplinary discussion. The investigators will prospectively follow the clinical course of patients after SLB for a period of 3 years to validate the diagnosis, and asses the diagnostic accuracy of molecular techniques.

NCT ID: NCT03824834 Recruiting - Clinical trials for Chronic Obstructive Pulmonary Disease

Morphine to Maximize the Benefits of Exercise Training in COPD or ILD and Persistent Breathlessness

MorEx
Start date: August 6, 2019
Phase: Phase 2
Study type: Interventional

The purpose of this study is to explore the role of low-dose immediate-release oral morphine as a novel adjunct pharmacotherapy to enable symptomatic adults with advanced chronic obstructive pulmonary disease (COPD) or interstitial lung disease (ILD) to exercise at higher intensities for longer durations and maximize the psycho-physiological benefits of a supervised exercise training program. We hypothesize that, compared to placebo, exercise training with oral morphine will result in relatively greater improvements in exercise endurance time and intensity ratings of perceived breathlessness during constant-load cardiopulmonary cycle exercise testing (CPET) at 75% of peak power output (PPO).

NCT ID: NCT03822780 Recruiting - Clinical trials for Surfactant Dysfunction

Hydroxychloroquin (HCQ) in chILD of Genetic Defect

Start date: July 1, 2017
Phase: N/A
Study type: Interventional

The purpose of this proposed research is to investigate the efficacy and safety of hydroxychloroquine sulfate (HCQ, Quensyl) for pediatric ILD(chILD) caused by pulmonary surfactant-associated genes mutations.

NCT ID: NCT03814317 Recruiting - Clinical trials for Interstitial Lung Disease

Inhaled Treprostinil in Sarcoidosis Patients With Pulmonary Hypertension

SAPPHIRE
Start date: January 30, 2020
Phase: Phase 2
Study type: Interventional

This study aims to evaluate the efficacy and safety of inhaled treprostinil in subjects with sarcoidosis-associated interstitial lung disease and pulmonary hypertension.

NCT ID: NCT03800914 Recruiting - Clinical trials for Fibrotic Interstitial Lung Disease

High Intensity Interval Training in Fibrotic Interstitial Lung Disease

HIIT in fILD
Start date: July 17, 2019
Phase: N/A
Study type: Interventional

The fibrotic interstitial lung diseases (fILD) is a group of debilitating chronic lung conditions that are characterised by scarring of lung tissue, dyspnoea on exertion and significant physical impairment. Exercise training is recommended for people with fILD in improving breathlessness and exercise tolerance. However, despite the best efforts of patients and clinicians, many of those who participate are not attaining its benefits. The current exercise training strategies of moderate intensity continuous training may not be well suited to fILD. High intensity interval training (HIIT), short bouts of high-intensity exercise regularly interspersed with periods of rest or light exercise may be an alternate exercise training option for people with fILD. The study will determine to whether HIIT is better than the current method of continuous exercise training at moderate intensity in improving exercise tolerance, breathlessness and quality of life in people with fILD. A randomised controlled, assessor blinded trial will be conducted. A total 130 people with fILD will be randomly assigned to moderate intensity continuous training or HIIT. If this trial demonstrates that HIIT is effective, it will provide an exercise training strategy that can readily be implemented in practice that will maximise the outcomes of exercise training for people with fILD.

NCT ID: NCT03770663 Recruiting - Clinical trials for Interstitial Lung Disease

Cyclophosphamide and Azathioprine vs Tacrolimus in Antisynthetase Syndrome-related Interstitial Lung Disease

CATR-PAT
Start date: February 5, 2021
Phase: Phase 3
Study type: Interventional

"Antisynthetase syndrome (ASS) is one of the most severe inflammatory myopathy (IM), due to pulmonary involvement (interstitial lung disease, ILD). Until now, the most commonly used immunosuppresive therapy in Europe is Cyclophosphamide followed by different immunosuppressive drugs as maintenance therapy, including Azathioprine (and so called " European Strategy "). In the USA however, the first-line immunosuppressive treatment is Tacrolimus (so called " American Strategy "). None of these two different strategies has ever been studied prospectively, and there is no clear comparison of short and long-term treatment efficacy and tolerance. Thus, there are yet no evidences helping the clinicians in the therapeutic management of patients with ASS-related ILD. The aim of this study is therefore to compare both strategies as first line treatments or in relapsing patients : CATR.PAT study is a 52 weeks, randomized, comparative, controlled, open-labeled, phase III, therapeutic clinical trial, comparing two treatment strategies."